Compare VVR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VVR | CLLS |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.9M | 394.4M |
| IPO Year | 1998 | 2014 |
| Metric | VVR | CLLS |
|---|---|---|
| Price | $2.95 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 534.5K | 16.1K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.93 | $2.35 |
| 52 Week High | $3.66 | $5.48 |
| Indicator | VVR | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 68.24 |
| Support Level | N/A | $3.41 |
| Resistance Level | $3.01 | $4.24 |
| Average True Range (ATR) | 0.02 | 0.18 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 16.67 | 99.12 |
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective is to provide a high level of current income, consistent with preservation of capital. The Trust seeks to achieve its objectives by investing in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions. The Trust borrows money for investment purposes, which may create the opportunity for enhanced return, but also should be considered a speculative technique and may increase the Trust's volatility.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.